What Kariya Pharmaceuticals does

Kariya Pharmaceuticals is a privately-held Danish biotechnology company founded in 2018 and headquartered at the BioInnovation Institute in Copenhagen. The company is developing KP405, a first-in-class dual incretin receptor co-agonist that targets both the GLP-1 and GIP receptors, as a disease-modifying treatment intended to slow the progression of Parkinson's Disease, with potential application in Alzheimer's Disease. KP405 has demonstrated clear superiority over existing single-receptor incretin therapies in multiple animal models of neurodegeneration and is currently Phase I ready, having completed toxicology studies under full Good Laboratory Practice (GLP) compliance in line with FDA and EMA requirements.

The company's technology platform is based on the well-established incretin biology linking GLP-1/GIP receptor activation to neuroprotective effects, including improved synaptic plasticity, induction of neurogenesis, normalization of growth factor signaling, reduction of neuroinflammation, and promotion of mitochondrial biogenesis. Clinical proof-of-concept for the incretin approach in Parkinson's has been demonstrated by the GLP-1 analogue Exenatide. Kariya differentiates itself through the dual-receptor design and extensive preclinical characterization in neurodegeneration models.

Kariya Pharmaceuticals is a pre-commercial company generating no product revenue. Its business model is structured around advancing KP405 through clinical development with the goal of securing a pharmaceutical licensing deal, co-development partnership, or acquisition once the asset reaches a commercially attractive inflection point. The company is currently funded by the Novo Nordisk Foundation's BioInnovation Institute and Innovation Fund Denmark, and is operationally supported through its CEO's Executive-in-Residence role at Novo Holdings. The leadership team consists of CEO Ian Laquian (ex-Nycomed/Takeda CNS franchise builder) and CSO Dr. Christian Hölscher (neuroscience professor with 180+ publications in neurodegeneration). The company has 1-10 employees and targets a Parkinson's Disease patient population of 3.4 million people across the eight major markets, where no approved disease-modifying therapies currently exist.

Name

Kariya Pharmaceuticals

Legal name

Kariya Pharmaceuticals ApS

Website

https://kariyapharma.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Kariya Pharmaceuticals is a Copenhagen-based pre-clinical biotech developing KP405, a first-in-class dual GLP-1/GIP receptor co-agonist designed to slow the progression of Parkinson's and Alzheimer's Disease, with a future revenue model centered on pharmaceutical licensing or acquisition.

Ownership category

akta.pro rank

Product category

Neurodegenerative Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Neurodegenerative disease therapeutics
• Incretin receptor agonists
• Parkinson's disease drugs
• Disease-modifying therapies
• Biopharmaceutical drug development

Headquarters

HQ city

Copenhagen

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Pharmaceutical Development and Licensing: Pre-commercial biotech company developing disease-modifying drugs for neurodegenerative diseases. Revenue generation will likely come from licensing deals, co-development partnerships, or acquisition as the lead compound KP405 advances through clinical development toward regulatory approval and commercialization.

Go-to-market motion1 record

Core offering

Kariya Pharmaceuticals is developing KP405, a first-in-class dual incretin receptor co-agonist designed to slow the progression of Parkinson's Disease by improving synaptic plasticity and reducing neuronal degeneration through multiple neuroprotective mechanisms. The compound has completed GLP-compliant toxicology studies and is Phase I ready, intended for out-licensing or co-development with larger pharmaceutical companies as it advances through clinical trials.

Product overview

Kariya Pharmaceuticals is developing a single lead compound, KP405, as a first-in-class dual incretin receptor co-agonist disease-modifying drug for neurodegenerative diseases. The company's product pipeline centers on KP405, which targets Parkinson's Disease with potential applications in Alzheimer's Disease, and has achieved Phase I readiness following successful GLP-compliant toxicology studies.

Differentiator

Problem solved

Functional benefit

Products and services

• KP405 KP405 is a first-in-class, dual incretin receptor co-agonist being developed to slow the progression of Parkinson's Disease. It targets both GLP-1 and GIP receptors to improve synaptic plasticity and reduce neuronal degeneration through multiple neuroprotective mechanisms, including neurogenesis, growth factor signaling normalization, reduced neuroinflammation, and mitochondrial biogenesis. KP405 has demonstrated clear superiority over existing incretin therapies in multiple animal models of neurodegeneration and is Phase I ready. The intended customers for the asset are large pharmaceutical companies seeking to license, co-develop, or acquire a Phase I-ready disease-modifying drug candidate for Parkinson's Disease.

Quantifiable outcome

• Efficacy demonstrated in multiple animal models of neurodegeneration with clear superiority over existing incretin therapies

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Direct peers

• Denali Therapeutics: Clinical-stage biotech developing disease-modifying therapeutics for neurodegeneration, including Parkinson's and Alzheimer's. Most directly comparable to Kariya in therapeutic area, modality (engineered biologics/peptides), and clinical stage.
• Prothena Corporation: Late clinical-stage biotech developing protein immunotherapies for neurodegenerative diseases including Parkinson's and Alzheimer's. Comparable in CNS therapeutic focus and biologics-based modality.
• Acadia Pharmaceuticals: Commercial CNS specialty pharmaceutical company with Parkinson's Disease and neurology franchises. Comparable CNS-focused drug development and commercialization model, though larger and revenue-generating.
• Sage Therapeutics: Biopharmaceutical company developing CNS therapeutics for neurological disorders. Comparable in CNS-focused small-molecule/biologic development and clinical-stage pipeline approach.
• Cognition Therapeutics: Clinical-stage biotech developing disease-modifying therapies for Alzheimer's Disease and other neurodegenerative disorders. Comparable in CNS pipeline focus, disease-modifying mechanism, and small-cap biotech profile.
• Alzheon: Clinical-stage biotech developing disease-modifying therapeutics for Alzheimer's Disease and neurodegeneration. Comparable in CNS pipeline, mechanism-based approach, and small private/early-public biotech profile.
• vTv Therapeutics: Clinical-stage pharmaceutical company developing therapeutics for CNS disorders and diabetes. Comparable in CNS pipeline focus and small-cap biotech profile with disease-modifying approaches.

Emerging players

• Neuraly (a D&J Company subsidiary): Clinical-stage company developing NLY01, a GLP-1 receptor agonist for Parkinson's Disease. Most directly comparable peer given the incretin mechanism overlap with Kariya's KP405 dual agonist approach.

Broad incumbents

• Eli Lilly: Major pharmaceutical company developing tirzepatide (dual GLP-1/GIP agonist) for metabolic disease, with broader CNS programs including Alzheimer's. Comparable via its incretin franchise and CNS pipeline investment, though broader in scope.
• Novo Nordisk: Global leader in GLP-1 receptor agonists (semaglutide/Ozempic) with active CNS/neurodegeneration research programs. Comparable as the dominant incumbent in incretin therapeutics and a potential acquirer/partner for Kariya.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kariya Pharmaceuticals